Literature DB >> 23990660

Telemonitoring and self-management in the control of hypertension (TASMINH2): a cost-effectiveness analysis.

Billingsley Kaambwa1, Stirling Bryan2, Sue Jowett3, Jonathan Mant4, Emma P Bray5, F D Richard Hobbs6, Roger Holder5, Miren I Jones5, Paul Little7, Bryan Williams8, Richard J McManus9.   

Abstract

AIMS: Self-monitoring and self-titration of antihypertensives (self-management) is a novel intervention which improves blood pressure control. However, little evidence exists regarding the cost-effectiveness of self-monitoring of blood pressure in general and self-management in particular. This study aimed to evaluate whether self-management of hypertension was cost-effective. DESIGN AND METHODS: A cohort Markov model-based probabilistic cost-effectiveness analysis was undertaken extrapolating to up to 35 years from cost and outcome data collected from the telemonitoring and self-management in hypertension trial (TASMINH2). Self-management of hypertension was compared with usual care in terms of lifetime costs, quality adjusted life years and cost-effectiveness using a UK Health Service perspective. Sensitivity analyses examined the effect of different time horizons and reduced effectiveness over time from self-management.
RESULTS: In the long-term, when compared with usual care, self-management was more effective by 0.24 and 0.12 quality adjusted life years (QALYs) gained per patient for men and women, respectively. The resultant incremental cost-effectiveness ratio for self-management was £1624 per QALY for men and £4923 per QALY for women. There was at least a 99% chance of the intervention being cost-effective for both sexes at a willingness to pay threshold of £20,000 per QALY gained. These results were robust to sensitivity analyses around the assumptions made, provided that the effects of self-management lasted at least two years for men and five years for women.
CONCLUSION: Self-monitoring with self-titration of antihypertensives and telemonitoring of blood pressure measurements not only reduces blood pressure, compared with usual care, but also represents a cost-effective use of health care resources. © The European Society of Cardiology 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Hypertension; cost-effectiveness; self-management; telemonitoring

Mesh:

Substances:

Year:  2013        PMID: 23990660     DOI: 10.1177/2047487313501886

Source DB:  PubMed          Journal:  Eur J Prev Cardiol        ISSN: 2047-4873            Impact factor:   7.804


  28 in total

1.  Performance and persistence of a blood pressure self-management intervention: telemonitoring and self-management in hypertension (TASMINH2) trial.

Authors:  E P Bray; M I Jones; M Banting; S Greenfield; F D R Hobbs; P Little; B Williams; R J Mcmanus
Journal:  J Hum Hypertens       Date:  2015-01-08       Impact factor: 3.012

2.  Pragmatic Method Using Blood Pressure Diaries to Assess Blood Pressure Control.

Authors:  James E Sharman; Leigh Blizzard; Wojciech Kosmala; Mark R Nelson
Journal:  Ann Fam Med       Date:  2016 Jan-Feb       Impact factor: 5.166

Review 3.  Economics of Self-Measured Blood Pressure Monitoring: A Community Guide Systematic Review.

Authors:  Verughese Jacob; Sajal K Chattopadhyay; Krista K Proia; David P Hopkins; Jeffrey Reynolds; Anilkrishna B Thota; Christopher D Jones; Daniel T Lackland; Kimberly J Rask; Nicolaas P Pronk; John M Clymer; Ron Z Goetzel
Journal:  Am J Prev Med       Date:  2017-08-14       Impact factor: 5.043

Review 4.  Systematic Review of Self-Measured Blood Pressure Monitoring With Support: Intervention Effectiveness and Cost.

Authors:  Sharada S Shantharam; Mallika Mahalingam; Aysha Rasool; Jeffrey A Reynolds; Aunima R Bhuiya; Tyra D Satchell; John M Chapel; Nikki A Hawkins; Christopher D Jones; Verughese Jacob; David P Hopkins
Journal:  Am J Prev Med       Date:  2021-10-20       Impact factor: 5.043

5.  An Integrated Community-Based Blood Pressure Telemonitoring Program - A Population-Based Observational Study.

Authors:  Ju-Yeh Yang; Yen-Wen Wu; Wenpo Chuang; Tzu-Chun Lin; Shu-Wen Chang; Shou-Hsia Cheng; Raymond N Kuo
Journal:  Acta Cardiol Sin       Date:  2022-09       Impact factor: 1.800

6.  Home Blood Pressure Self-monitoring plus Self-titration of Antihypertensive Medication for Poorly Controlled Hypertension in Primary Care: the ADAMPA Randomized Clinical Trial.

Authors:  Patricia Martínez-Ibáñez; Irene Marco-Moreno; Salvador Peiró; Lucia Martínez-Ibáñez; Ignacio Barreira-Franch; Laura Bellot-Pujalte; Eugenia Avelino-Hidalgo; Marina Escrig-Veses; María Bóveda-García; Mercedes Calleja-Del-Ser; Andreu Ferrero-Gregori; Adina A Iftimi; Isabel Hurtado; Aníbal García-Sempere; Clara L Rodríguez-Bernal; Margarita Giménez-Loreiro; Gabriel Sanfélix-Gimeno; José Sanfélix-Genovés
Journal:  J Gen Intern Med       Date:  2022-10-11       Impact factor: 6.473

7.  Pharmacist-led hypertension management combined with blood pressure telemonitoring in a primary care setting may be cost-effective in high-risk patients.

Authors:  Stefano Omboni
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-12-20       Impact factor: 3.738

8.  Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.

Authors:  Melissa J Palmer; Kazuyo Machiyama; Susannah Woodd; Anasztazia Gubijev; Sharmani Barnard; Sophie Russell; Pablo Perel; Caroline Free
Journal:  Cochrane Database Syst Rev       Date:  2021-03-26

Review 9.  Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.

Authors:  Melissa J Palmer; Sharmani Barnard; Pablo Perel; Caroline Free
Journal:  Cochrane Database Syst Rev       Date:  2018-06-22

Review 10.  What is the evidence base for diagnosing hypertension and for subsequent blood pressure treatment targets in the prevention of cardiovascular disease?

Authors:  Claire L Schwartz; Richard J McManus
Journal:  BMC Med       Date:  2015-10-12       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.